Learn how to interpret your PSMA-PET scan results, understand SUV metrics, and track metastatic prostate cancer treatment options and progress.

A 58-year-old businessman walks into a clinic for a routine health check. He feels fine. No pain, no urinary trouble, nothing ...

PSMA therapy is a targeted treatment for metastatic prostate cancer that uses radioligand therapy to slow disease progression and improve quality of life.

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about the role of PSMA-PET Imaging versus PSA. Prostate specific antigen (PSA) is a ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

Case report highlights the importance of a multidisciplinary, evidence-based approach to treating prostate cancer that ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...

Over the past decade or so, prostate-specific membrane antigen (PSMA) PET/CT has increasingly replaced conventional imaging in men with biochemical recurrence after radical prostatectomy. PSMA PET/CT ...

The novel PET imaging agent detected significantly more PSMA-positive prostate cancer lesions vs SOC in patients with low PSA levels. The experimental agent met the primary end point and demonstrated ...

Among patients treated in the PSMAtrack analysis, all had residual PSMA-avid disease following 6 months of systemic therapy for metastatic HSPC. Prostate-specific membrane antigen (PSMA)–PET and PSA ...

FDA Fast Track designation granted for Telix's BiPASS® program, which is evaluating 68Ga-PSMA-PET imaging alongside MRI in the pre-biopsy prostate cancer setting.The designation recognizes the program ...